GUIDELINES FOR INSERTION OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS

AMERICAN COLLEGE OF CARDIOLOGY, AMERICAN HEART ASSOCIATION, AND HEART RHYTHM SOCIETY GUIDELINES FOR INSERTION OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS

CARDIOVERTER-DEFIBRILLATOR


Class I Heart Failure:

• Survivors of cardiac arrest due to VF (ventricular fibrillation) or sustained VT (ventricular tachycardia) after excluding reversible causes

• Patients with structural heart disease and spontaneous, sustained VT, whether hemodynamically stable or unstable

• Patients with syncope of undetermined origin with clinically relevant sustained VT or VF induced at electrophysiology study


• Patients with an LVEF ≤35% due to prior MI occurring at least 40 days earlier and who have NYHA functional class II or III disease

• Patients with nonischemic dilated cardiomyopathy who have an LVEF ≤35% and NYHA functional class II or III disease

• Patients with LV dysfunction due to prior MI occurring at least 40 days earlier with an LVEF ≥30% and who have NYHA class I disease

• Patients with nonsustained VT due to prior MI with an LVEF ≤40% with inducible VF or sustained VT at electrophysiology study

Class IIa Heart Failure

• Patients with unexplained syncope, LV dysfunction, and nonischemic cardiomyopathy

• Patients with sustained VT and normal LV function

• Patients with hypertrophic cardiomyopathy and at least one risk factor for sudden cardiac death

• Patients with arrhythmogenic RV dysplasia with at least one risk factor for sudden cardiac death

• Patients with long QT syndrome with syncope and/or sustained VT while on β-blockers

• Nonhospitalized patients awaiting heart transplantation

• Patients with Brugada syndrome who have syncope or those with documented VT not resulting in cardiac arrest

• Patients with catecholaminergic polymorphic VT who have syncope and/or documented sustained VT while receiving β-blockers

• Patients with cardiac sarcoidosis, giant cell myocarditis or Chagas disease


Class IIb Heart Failure

• Patients with nonischemic heart disease who have an LVEF ≤35% and who have NYHA class I disease

• Patients with long QT syndrome and risk factors for sudden cardiac death

• Patients with syncope and structural heart disease when evaluation has failed to define a cause

• Patients with familial cardiomyopathy associated with sudden cardiac death

• Patients with LV noncompaction

Class III Heart Failure

• ICD implantation not indicated for patients whose reasonable life expectancy at an acceptable functional status is <1 year even if they meet other criteria

Therapeutic Indications by Functional Class

• Class I: There is evidence or general agreement that the treatment is useful and effective.

• Class IIa: Weight of the data or evidence favors benefit of the therapy.

• Class IIb: The conditions for which usefulness or efficacy of the treatment are less well established.

• Class III: Intervention is not indicated.


Popular posts from this blog

Ketamine: The Past, Present, and Potential Future of an Anesthetic Drug

Ketamine is a powerful anesthetic drug that has been used in medical settings for decades. However, its effects on the brain have also led to its use as a recreational drug, leading to controversy surrounding its use. Despite its negative associations, recent research has shown promising potential for the drug in the treatment of mental health conditions such as depression and post-traumatic stress disorder (PTSD).
Read more

Fast track anesthesia approaches

  Fast track anesthesia schemes are multi-modal approaches that aim to reduce the physiological stress response to surgery, enhance recovery, and improve patient outcomes. These schemes typically involve several aspects of perioperative care, including anesthesia management, surgical technique, pain management, fluid management, and early mobilization. Here are some common fast track anesthesia schemes:
Read more